Table 2.
Outcome ascertainment and follow-up of included International epidemiologic Databases to Evaluate AIDS (IeDEA) facilities (n = 137)
| Category and variables | West Africa (n = 21) | Southern Africa (n = 19) | East Africa (n = 43) | Central Africa (n = 12a) | South America (n = 7) | Asia (n = 28b) | North America (n = 7c) | Total (n = 137) |
|---|---|---|---|---|---|---|---|---|
| Follow-up of key populations | ||||||||
| Pregnant women | ||||||||
| Yes | 6 (28.6) | 0 (0) | 37 (86.0) | 8 (66.7) | 4 (57.1) | 4 (14.3) | 0 (0) | 59 (43.1) |
| No | 6 (28.6) | 0 (0) | 0 (0) | 1 (8.3) | 0 (0) | 5 (17.9) | 0 (0) | 12 (8.8) |
| Missing | 9 (42.9) | 19 (100) | 6 (14.0) | 3 (25.0) | 3 (42.9) | 19 (67.9) | 7 (100) | 66 (48.2) |
| Children, HIV-exposed and/or HIV-infected | ||||||||
| Yes | 13 (61.9) | 0 (0) | 38 (88.4) | 11 (91.7) | 4 (57.1) | 12 (42.9) | 0 (0) | 78 (56.2) |
| Missing | 8 (38.1) | 19 (100) | 5 (11.6) | 1 (8.3) | 3 (42.9) | 16 (57.1) | 7 (100) | 59 (43.8) |
| Presence of an outreach program for patients who miss visits or become LTFU | ||||||||
| Yes | 9 (42.9) | 0 (0) | 39 (90.7) | 6 (50.0) | 3 (43.9) | 11 (39.3) | 5 (71.4) | 73 (53.3) |
| Missing | 12 (57.1) | 19 (100) | 4 (9.3) | 6 (50.0) | 4 (57.1) | 17 (60.7) | 2 (28.6) | 64 (46.7) |
| Active outreach | ||||||||
| Call only | 1 (4.8) | 5 (26.3) | 1 (2.3) | 0 (0) | 0 (0) | 12 (42.9) | 6 (85.7) | 25 (18.2) |
| Call and home visit by clinic staff or outreach workers | 11 (52.4) | 12 (63.2) | 32 (74.4) | 9 (0.75) | 2 (28.6) | 6 (21.4) | 0 (0) | 72 (52.6) |
| Home visit only | 1 (4.8) | 2 (10.5) | 8 (18.6) | 2 (16.7) | 0 (0) | 0 (0) | 0 (0) | 13 (9.5) |
| Missing | 8 (38.1) | 0 (0) | 2 (4.7) | 1 (8.3) | 5 (71.4) | 10 (35.7) | 1 (14.3) | 27 (19.7) |
| Ascertainment of deaths | ||||||||
| Active | 7 (33.3) | 0 (0) | 32 (74.4) | 5 (41.7) | 3 (42.9) | 2 (7.1) | 4 (57.1) | 53 (38.7) |
| Missing | 14 (66.7) | 19 (100) | 11 (25.6) | 7 (58.3) | 4 (57.1) | 26 (92.9) | 3 (42.9) | 84 (61.3) |
| Methods of death ascertainment (multiple methods provided) | ||||||||
| Family | 12 (57.1) | 0 (0) | 37 (86.1) | 9 (75) | 7 (100) | 15 (53.6) | 6 (85.7) | 86 (62.8) |
| Word of mouth | 3 (14.3) | 0 (0) | 32 (74.4) | 6 (50) | 2 (28.6) | 6 (21.4) | 4 (57.1) | 53 (38.7) |
| Physician report | 5 (23.8) | 0 (0) | 32 (74.4) | 4 (33.3) | 5 (71.4) | 17 (60.7) | 7 (100) | 70 (51.7) |
| Data linkage with patient records | 2 (9.5) | 11 (57.9) | 25 (58.1) | 1 (8.3) | 4 (57.1) | 6 (21.4) | 6 (85.7) | 55 (40.1) |
| Phone follow-up | 11 (5.2) | 0 (0) | 27 (62.8) | 6 (50) | 5 (71.4) | 10 (35.7) | 4 (57.1) | 63 (46.0) |
| Home follow-up | 8 (38.1) | 0 (0) | 33 (76.7) | 9 (75) | 1 (14.3) | 2 (7.1) | 1 (14.3) | 54 (39.4) |
| Other | 2 (9.5) | 0 (0) | 0 (0) | 0 (0) | 1 (14.3) | 0 (0) | 0 (0) | 3 (2.2) |
| Missing | 7 (33.3) | 8 (42.1) | 0 (0) | 0 (0) | 0 (0) | 7 (25) | 0 (0) | 22 (16.1) |
| Payment structure (user fees) | ||||||||
| General | ||||||||
| Full/partial payment | 2 (9.5) | 5 (26.3) | 2 (4.7) | 3 (12.5) | 3 (42.9) | 10 (35.7) | 0 (0) | 25 (18.2) |
| No fees | 15 (71.4) | 14 (73.7) | 41 (95.3) | 9 (75) | 4 (57.1) | 18 (64.3) | 7 (100) | 108 (78.8) |
| Missing | 4 (19) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (2.9) |
| Diagnostic exams | ||||||||
| Full/partial payment | 5 (23.8) | 2 (10.5) | 4 (9.3) | 4 (33.3) | 3 (42.9) | 9 (32.1) | 0 (0) | 27 (19.7) |
| No fees | 11 (52.4) | 17 (89.5) | 39 (90.7) | 8 (66.7) | 4 (57.1) | 17 (60.7) | 7 (100) | 103 (75.2) |
| Missing | 5 (23.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (7.1) | 0 (0) | 7 (5.1) |
| Routine follow-up | ||||||||
| Full/partial payment | 6 (28.6) | 3 (15.8) | 0 (0) | 2 (16.7) | 2 (28.6) | 10 (35.7) | 0 (0) | 23 (16.8) |
| No fees | 11 (52.4) | 16 (84.2) | 43 (100) | 10 (83.3) | 5 (71.4) | 18 (64.3) | 7 (100) | 110 (80.3) |
| Missing | 4 (19) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (2.9) |
| Additional consultation | ||||||||
| Full/partial payment | 9 (42.9) | 3 (15.8) | 3 (7) | 4 (33.3) | 2 (28.6) | 9 (32.1) | 0 (0) | 30 (21.9) |
| No fees | 8 (38.1) | 16 (84.2) | 40 (93) | 8 (66.7) | 5 (71.4) | 19 (67.9) | 7 (100) | 103 (75.1) |
| Missing | 4 (19) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (2.9) |
| Laboratory | ||||||||
| Full/partial payment | 8 (38.1) | 2 (10.5) | 4 (9.3) | 6 (50) | 3 (42.9) | 10 (35.7) | 0 (0) | 33 (24.1) |
| No fees | 9 (42.9) | 17 (89.5) | 39 (90.7) | 6 (50) | 4 (57.1) | 18 (64.3) | 7 (100) | 100 (73.0) |
| Missing | 4 (19) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (2.9) |
| First/second-line ARVs | ||||||||
| Full/partial payment | 1 (4.8) | 2 (10.5) | 0 (0) | 0 (0) | 1 (14.3) | 9 (32.1) | 0 (0) | 13 (9.5) |
| No fees | 16 (76.2) | 17 (89.5) | 43 (100) | 12 (100) | 6 (85.7) | 19 (67.9) | 7 (100) | 120 (87.6) |
| Missing | 4 (19) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (2.9) |
| Prophylaxis/treatment for opportunistic infections | ||||||||
| Full/partial payment | 9 (42.9) | 3 (15.8) | 0 (0) | 6 (50) | 3 (42.9) | 12 (42.9) | 0 (0) | 33 (24.1) |
| No fees | 8 (38.1) | 16 (84.2) | 43 (100) | 6 (50) | 4 (57.1) | 16 (57.1) | 7 (100) | 100 (73.0) |
| Missing | 4 (19) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (2.9) |
| Travel to the clinic | ||||||||
| Full/partial payment | 12 (57.1) | 15 (78.9) | 39 (90.7) | 12 (100) | 5 (71.4) | 22 (78.6) | 3 (42.9) | 108 (78.8) |
| No fees | 5 (23.8) | 4 (21.1) | 4 (9.3) | 0 (0) | 2 (28.5) | 6 (21.4) | 4 (57.1) | 25 (18.2) |
| Missing | 4 (19) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (2.9) |
The data are presented as n (%). No data were available for “routine clinical monitoring and follow-up” or “standard operating procedures in place (clinical, laboratory, pharmacovigilance reporting)”
ARVs antiretrovirals, LTFU lost to follow-up
aCentral Africa has 15 facilities but no data were available for three facilities
bAsia–Pacific Region has 29 facilities but no data were available for one facility
cNorth America has eight facilities but no data were available for one facility